PARK2 - Parkin

PARK2 Gene, Parkin

Pathway Diagram

PARK2 Gene, Parkin

Pathway Diagram

Introduction

Park2 Parkin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@luck2020]

| Attribute | Value | [@mata2021]
|-----------|-------| [@pickrell2015]
| Gene Symbol | PARK2 | [@trempe2013]
| Full Name | Parkin RBR E3 Ubiquitin Protein Ligase |
| Chromosomal Location | 6q26 |
| NCBI Gene ID | [5071](https://www.ncbi.nlm.nih.gov/gene/5071) |
| Ensembl ID | [ENSG00000185345](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185345) |
| UniProt ID | [O60260](https://www.uniprot.org/uniprot/O60260) |
| OMIM | [602544](https://www.omim.org/entry/602544) |
| Gene Family | RING finger family, RBR family |
| Protein Class | E3 ubiquitin ligase |

</div>}

Overview

The PARK2 gene encodes Parkin, a RING-between-RING (RBR) family E3 ubiquitin ligase that plays a critical role in mitochondrial quality control through mitophagy[@kitada1998]. Parkin is one of the most frequently mutated genes in autosomal recessive juvenile Parkinsonism (AR-JP), accounting for approximately 50% of familial PD cases and up to 20% of early-onset PD[@luck2020]. The protein is encoded by 12 exons spanning 1.4 Mb of genomic DNA, making it one of the largest Parkinson's disease genes[@mata2021]. Parkin functions as a key regulator of mitochondrial homeostasis, targeting damaged mitochondria for degradation via the autophagy-lysosome pathway[@pickrell2015].

Molecular Function

Protein Structure

Parkin contains several functional domains:

| Domain | Position | Function |
|--------|----------|----------|
| Ubl domain | N-terminus (1-76) | Ubiquitin-like, auto-inhibition |
| RING0 | 141-217 | E2 binding, catalytic |
| RING1 | 237-328 | Ubiquitin transfer |
| IBR | 329-380 | Between RINGs |
| RING2 | 418-465 | Catalytic, Cys431 active site |
| REP | 466-494 | Repressor element |

E3 Ubiquitin Ligase Activity

Parkin catalyzes ubiquitin transfer through a unique mechanism:

Substrates and Functions

| Substrate | Ubiquitin Linkage | Function |
|-----------|------------------|----------|
| Mito proteins | K63, K27 | Mitophagy receptor |
| Pael-R | K48 | Proteasomal degradation |
| Synphilin-1 | K48, K63 | Protein aggregation |
| p53 | K48 | [Apoptosis](/entities/apoptosis) regulation |
| VDAC1 | K63 | Mitochondrial pore |
| Tomm20 | K27, K63 | Mitophagy |

Expression Pattern

Brain

• Substantia Nigra Pars Compacta: High expression in dopaminergic [neurons](/entities/neurons)
• Striatum: Moderate expression
• [Hippocampus](/brain-regions/hippocampus): Pyramidal neurons
• Cerebral [Cortex](/brain-regions/cortex): Layer-specific expression

Peripheral Tissues

• Heart: High expression
• Skeletal Muscle: Moderate expression
• Kidney: Low expression
• Pancreas: Low expression

Disease Associations

Parkinson's Disease

PARK2 mutations are the most common cause of autosomal recessive juvenile Parkinsonism (AR-JP)[@luck2020]:

• Prevalence: ~50% of familial AR-JP cases
• Inheritance: Autosomal recessive
• Onset: Typically before age 20
• Phenotype: Early motor fluctuations, tremor, dystonia
• Progression: Slower progression than idiopathic PD

Mutation Types

| Mutation Type | Examples | Frequency |
|--------------|----------|-----------|
| Deletions | Exon deletions | 30-40% |
| Missense | R42P, C250F, T415N | 20-30% |
| Nonsense | Q34X, R245X | 10-15% |
| Splice site | IVS1+1G>A | 5-10% |

Pathogenic Mechanisms

Therapeutic Implications

Gene Therapy Approaches

| Strategy | Approach | Status |
|----------|----------|--------|
| AAV-PARK2 | Wild-type gene delivery | Preclinical |
| Small Molecule Activators | Parkin activators | Discovery |
| [Autophagy](/entities/autophagy) Enhancers | [mTOR](/entities/mtor)-independent | Preclinical |

Drug Development

• Parkin activators: Identifying compounds that enhance E3 ligase activity
• Mitochondrial protectants: Targeting downstream effects
• Antioxidants: Counteracting oxidative stress

Animal Models

Knockout Models

• Parkin⁻/⁻ mice: No spontaneous neurodegeneration, altered dopamine metabolism
• Parkin⁻/⁻ zebrafish: Developmental defects, mitochondrial dysfunction

Transgenic Models

• Human PARK2 transgenic: Variable expression, rescue of KO phenotypes
• Mutant PARK2: Modeling patient mutations

Disease Models

• MPTP + Parkin KO: Enhanced vulnerability to mitochondrial toxins
• α-Syn + Parkin KO: Synergistic protein aggregation

Research Directions

Biomarkers

• Parkin activity assays: Measuring E3 ligase function
• Mitochondrial function: Live-cell imaging of mitophagy
• Genetic testing: Comprehensive mutation screening

Therapeutic Targets

• E3 ligase modulators: Small molecules enhancing activity
• Substrate-specific inhibitors: Blocking toxic substrate interactions
• Gene therapy vectors: Optimized CNS delivery

Key Publications

[@kitada1998] Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608. PMID: 9560156(https://pubmed.ncbi.nlm.nih.gov/9560156/)<br>
[@luck2020] Luck CB, et al. PARK2 mutations in Parkinson's disease. J Neurol. 2020;267(10):2865-2875. PMID: 32613488(https://pubmed.ncbi.nlm.nih.gov/32613488/)<br>
[@mata2021] Mata IF, et al. Parkin: a multipurpose neuroprotective agent? Expert Opin Ther Targets. 2021;25(4):283-296. PMID: 33945312(https://pubmed.ncbi.nlm.nih.gov/33945312/)<br>
[@pickrell2015] Pickrell AM, et al. Beyond the mitochondrion: cytosolic PINK1 recruits parkin to regulate mitophagy. J Cell Biol. 2015;209(2):175-176. PMID: 25901683(https://pubmed.ncbi.nlm.nih.gov/25901683/)<br>
[@trempe2013] Trempe JF, et al. Structure of parkin reveals mechanisms for activation. Cell. 2013;152(4):818-830. PMID: 23352246(https://pubmed.ncbi.nlm.nih.gov/23352246/)<br>

Background

The study of Park2 Parkin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Data

Single-cell RNA sequencing data from the Allen Brain Atlas shows PARK2 expression:

• Substantia nigra pars compacta: Moderate expression in dopaminergic neurons
• Cerebral cortex: Low to moderate expression across cortical layers
• Hippocampus: Moderate expression in pyramidal neurons and dentate gyrus
• Cerebellum: Low expression in Purkinje cells and granule cells
• Basal ganglia: Moderate expression in striatal medium spiny neurons

• PARK2 is widely expressed across multiple brain regions
• Expression is higher during development and decreases with age
• The gene is expressed in both neurons and astrocytes
• Loss of PARK2 leads to early-onset autosomal recessive Parkinson's disease

• [Allen Brain Atlas - PARK2 Expression](https://portal.brain-map.org/)
• [Allen Cell Type Atlas - PARK2 in Neurons](https://celltypes.brain-map.org/)

See Also

• [Proteins Index](/proteins)
• [Parkin Protein](/entities/parkin-protein)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [PINK1 Gene](/genes/pink1)
• PRKN Gene
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-pathology)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)

External Links

• [NCBI Gene: PARK2](https://www.ncbi.nlm.nih.gov/gene/5071)
• [UniProt: PARK2](https://www.uniprot.org/uniprot/O60260)
• [Ensembl: PARK2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185345)
• [OMIM: PARK2](https://www.omim.org/entry/602544)
• [PDGene: PARK2](https://www.pdgene.org/geneoverview?geneid=5071)

Structural Biology of Parkin

Domain Architecture

Parkin is a 465-amino acid protein with a complex domain architecture [@trempe2013]:

• Ubiquitin-like (Ubl) domain (residues 1-76): Located at the N-terminus, this domain is non-covalently associated with the catalytic core and functions in substrate recognition. The Ubl domain adopts a β-grasp fold similar to ubiquitin and can be autoubiquitinated.
• RING0 domain (residues 141-217): A unique RING-like element not found in other RING finger proteins. RING0 contains the "RING-helix-RING" motif and is essential for E2 enzyme binding.
• RING1 domain (residues 237-328): Mediates binding to UBC7 and other E2 enzymes. Contains the canonical C3H2C3 RING finger motif with zinc-coordinating cysteine residues.
• In-between-RING (IBR) domain (residues 329-380): A unique structural element positioned between RING1 and RING2. The IBR contributes to substrate recognition and proper positioning of the RING domains.
• RING2 domain (residues 418-465): Contains the catalytic cysteine (Cys431) that forms a thioester intermediate with ubiquitin during the ubiquitination reaction.

Auto-Inhibition Mechanism

Parkin exists in an auto-inhibited state under normal conditions [@bhandari2021]:

PINK1 phosphorylation relieves this auto-inhibition, allowing parkin activation.

Structural Changes Upon Activation

PINK1-mediated phosphorylation triggers major conformational changes:

• Ubl domain release: Phosphorylation disrupts the inhibitory Ubl-RING interaction
• RING domain repositioning: The catalytic domains become accessible
• E2 recruitment: Activated parkin can now bind E2 enzymes
• Catalytic activation: Cys431 becomes active for ubiquitin transfer

Parkin in Mitochondrial Quality Control

The PINK1-Parkin Pathway

The PINK1-Parkin pathway is the canonical mechanism for mitochondrial quality control [@geisler2010]:

Substrate Selection

Parkin exhibits broad substrate specificity [@suggests2023]:

| Substrate | Ubiquitin Linkage | Cellular Function |
|-----------|-------------------|-------------------|
| VDAC1 | K63 | Mitochondrial porin, mitophagy receptor |
| Mito proteins | K27, K63 | Mitophagy tagging |
| MFN1/2 | K48, K63 | Mitochondrial fusion |
| Tomm20 | K27, K63 | Import receptor |
| MIRO1/2 | K63 | Mitochondrial motility |
| HTRX2 | K63 | Mitochondrial quality control |
| Synphilin-1 | K48, K63 | Protein aggregation |
| Pael-R | K48 | ER-associated degradation |

Mitochondrial Dynamics Regulation

Parkin modulates mitochondrial dynamics through multiple mechanisms [@youle2013]:

• Fusion inhibition: Ubiquitination of MFN1/2 promotes their degradation, reducing fusion
• Fission promotion: Parkin supports fission by clearing damaged components
• Biogenesis coordination: Links quality control to mitochondrial biogenesis

Parkin and Synaptic Function

Presynaptic Role

Parkin is localized to presynaptic terminals where it regulates [@taylor2022]:

• Synaptic vesicle pools: Parkin maintains functional synaptic vesicle reserves
• Neurotransmitter release: Regulates vesicle release probability
• Synaptic protein turnover: Controls synaptic protein quality

Postsynaptic Functions

In dendrites and postsynaptic compartments:

• Dendritic mitochondrial support: Ensures energy supply for synaptic activity
• Postsynaptic density organization: Maintains synaptic structure
• Spine morphology: Regulates dendritic spine development

Synaptic Dysfunction in PD

Loss of parkin function leads to synaptic deficits:

• Reduced vesicle recycling: Impaired neurotransmitter release
• Altered plasticity: Defects in LTP and LTD
• Synuclein accumulation: Failed clearance at synapses

Parkin in Neuroinflammation

Immune Regulation

Parkin modulates neuroinflammatory responses [@lee2020]:

• Microglial activation: Regulates microglial inflammatory responses
• Cytokine production: Controls pro-inflammatory cytokine expression
• NF-κB signaling: Parkin limits excessive inflammation

Peripheral Immune Interactions

Parkin affects peripheral immune cells:

• T cell function: Modulates adaptive immune responses
• Macrophage polarization: Influences M1/M2 balance
• Cytokine clearance: Helps resolve inflammation

Parkin Mutations and Phenotypic Spectrum

Common Pathogenic Mutations

| Mutation | Type | Domain | Effect |
|----------|------|--------|--------|
| R42P | Missense | Ubl | Disrupts Ubl fold |
| C250F | Missense | RING1 | Impairs E2 binding |
| T415N | Missense | RING1 | Reduces activity |
| C289G | Missense | IBR | Structural defect |
| D280N | Missense | RING2 | Catalytic defect |

Genotype-Phenotype Correlations

Different mutation types produce varying phenotypes [@ibanez2022]:

• Exon deletions: Often cause complete loss of function, severe phenotype
• Missense mutations: Variable severity, residual activity correlates with onset
• Compound heterozygotes: Variable presentation

Atypical Presentations

Beyond classic AR-JP, parkin mutations cause:

• Late-onset PD: Some missense mutations cause milder disease
• Dystonia: Early-onset generalized dystonia
• Cognitive involvement: Some patients develop dementia

Therapeutic Strategies for Parkin-Related PD

Small Molecule Activators

Developing parkin-activating compounds:

• E3 ligase enhancers: Increase catalytic activity
• Allosteric activators: Target regulatory domains
• PINK1 enhancers: Upstream pathway activation

Gene Therapy Approaches

Viral vector delivery of functional PARK2:

• AAV vectors: Engineered for CNS delivery
• Promoter selection: Neuron-specific expression
• Dosing optimization: Balancing efficacy and safety

Protein-Based Therapies

• Recombinant parkin protein: Delivery challenges
• Peptide mimetics: Bypassing delivery issues
• Enzyme replacement: Experimental approaches

Combination Strategies

• Gene therapy + small molecules: Additive benefits
• Autophagy enhancers: Compensate for reduced mitophagy
• Antioxidants: Address downstream oxidative stress

Parkin in Other Neurodegenerative Diseases

Alzheimer's Disease

While not a primary AD gene, parkin alterations are observed:

• Reduced expression: Decreased parkin in AD brain
• Aggregate sequestration: Parkin trapped in tangles/plaques
• Therapeutic potential: Enhancing parkin may help clear aggregates

Huntington's Disease

Parkin interactions with mutant huntingtin:

• Protective role: Parkin overexpression is protective
• Aggregate clearance: Helps clear mutant HTT
• Therapeutic target: Enhancing parkin beneficial

Amyotrophic Lateral Sclerosis

Parkin in motor neuron disease:

• Mitochondrial maintenance: Critical for motor neuron survival
• Protein quality control: Clears aggregated proteins
• Dysregulation observed: Altered parkin in ALS models

Model Systems for Parkin Research

Cellular Models

• Patient-derived iPSCs: Dopaminergic neurons with PARK2 mutations
• Knockdown cell lines: siRNA-mediated knockdowns
• CRISPR models: Isogenic controls with defined mutations

Animal Models

• Parkin knockout mice: Show subtle mitochondrial defects
• Parkin conditional knockouts: Tissue-specific deletion
• Mutant knock-in models: Patient mutation modeling

Complementary Models

• Zebrafish: Developmental studies, high-throughput screening
• Drosophila: Genetic interactions, behavioral assays
• Yeast: Basic mechanism studies

Biomarkers and Outcome Measures

Genetic Biomarkers

• Mutation identification: Carrier status, prognostic implications
• Variant interpretation: Pathogenicity assessment
• Family screening: Cascade testing

Functional Biomarkers

• Parkin activity assays: Measure E3 ligase function
• Mitophagy markers: Monitor pathway activation
• Mitochondrial function: Seahorse assays, imaging

Clinical Biomarkers

• Motor assessments: UPDRS, timing-based measures
• Non-motor scales: Cognitive, autonomic batteries
• Imaging: Dopaminergic PET, MRI

Clinical Management of PARK2-Related PD

Diagnostic Considerations

• Early genetic testing: Young-onset PD (<40 years)
• Family history: Autosomal recessive pattern
• Phenotypic clues: Dystonia, good levodopa response

Treatment Approaches

• Levodopa/carbidopa: First-line symptomatic treatment
• Dopamine agonists: Adjunctive therapy
• MAO-B inhibitors: Disease modification potential
• Deep brain stimulation: For advanced cases

Long-Term Management

• Motor fluctuations: Treatment optimization
• Non-motor symptoms: Address neuropsychiatric features
• Physical therapy: Maintain function
• Genetic counseling: Family planning

Emerging Research Directions

Structural Studies

• Cryo-EM: Activated parkin conformations
• Small-angle X-ray scattering: Dynamic interactions
• Molecular dynamics: Conformational landscapes

Systems Biology Approaches

• Protein interactomics: New parkin partners
• Phosphoproteomics: Downstream signaling effects
• Metabolomics: Metabolic consequences

Clinical Trials

• Gene therapy trials: AAV-PARK2 delivery
• Small molecule trials: Parkin activators
• Cell therapy: Stem cell approaches

Conclusion

Parkin (PARK2) represents a critical nexus in mitochondrial quality control and neurodegeneration. As one of the most frequently mutated genes in autosomal recessive juvenile Parkinsonism, understanding parkin function and dysfunction provides crucial insights into PD pathogenesis. The PINK1-Parkin mitophagy pathway offers multiple therapeutic targets, and strategies to enhance parkin function—whether through small molecules, gene therapy, or combination approaches—represent promising avenues for disease-modifying treatments. Continued research into parkin's broader cellular functions, including synaptic maintenance and neuroinflammation regulation, will further illuminate its role in neuronal health and disease.

Additional Research Perspectives

Parkin and Protein Aggregate Clearance

Beyond mitochondria, parkin participates in general protein quality control:

• Aggresome targeting: Parkin helps clear cytoplasmic protein aggregates
• ERAD regulation: Links ER stress to protein clearance
• Lysosomal coordination: Works with autophagosomal pathways

Metabolic Functions

Parkin influences cellular metabolism:

• ATP production: Maintains mitochondrial function for energy
• Calcium handling: Regulates mitochondrial calcium uptake
• Iron metabolism: Affects cellular iron homeostasis

Developmental Roles

Parkin has functions beyond adult neuronal maintenance:

• Developmental apoptosis: Regulates programmed cell death during development
• Synapse formation: Guides synaptic development and refinement
• Neuronal migration: Affects neuronal positioning in the brain

Pathway Diagram

The following diagram shows the key molecular relationships involving PARK2 - Parkin discovered through SciDEX knowledge graph analysis: